Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 5Phase 1 4Phase EARLY_PHASE1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 82Glioma 65Brain Neoplasms 60Neuroblastoma 14Astrocytoma 14Neoplasms 10Medulloblastoma 9Oligodendroglioma 8Gliosarcoma 8Breast Neoplasms 8Meningioma 7Diffuse Intrinsic Pontine Glioma 7Central Nervous System Neoplasms 7Recurrence 6Neoplasm Metastasis 6Lung Neoplasms 6Ependymoma 6Sarcoma 5Melanoma 5Neuroma, Acoustic 4Lymphoma, Follicular 4Squamous Cell Carcinoma of Head and Neck 3Rhabdoid Tumor 3Prostatic Neoplasms 3Pheochromocytoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Osteosarcoma 3Neurofibromatosis 2 3Colonic Neoplasms 3

Interventions

nilotinib 1Ranibizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neurofibroma × CNS × Clear all
NCT01275586 2017-04-12

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Indiana University

Phase EARLY_PHASE1 Completed
6 enrolled 7 charts
CNS

Neurofibroma, Neurofibromatoses, Neurofibroma, Plexiform

NCT00657202 2016-07-07

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Massachusetts General Hospital

Phase EARLY_PHASE1 Completed
11 enrolled
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡